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Abstract
Introduction: Toll-like receptors (TLRs) are a family of pattern recognition receptors that are expressed on cells of
the innate immune system. The ligands can be pathogen derived (pathogen associated molecular patterns; PAMPs)
or endogenous (damage associated molecular patters; DAMPs) that when bound induces activation of nuclear
factor kappa B (NF-κB) and transcription of pro-inflammatory genes. TLRs have also been discovered in various
malignant cell types, but with unknown function.
Methods: In this study we performed a detailed analysis of TLR and co-receptor expression pattern and function in
breast cancer. Expression patterns were examined using real-time quantitative polymerase chain reaction (RT-qPCR)
and immunohistochemistry (IHC) on three estrogen receptor-positive (ER+) and four estrogen receptor/progesterone
receptor-negative (ER−/PR−; ER/PR-negative) breast cancer cell lines, and a breast cancer cohort consisting of 144
primary breast cancer samples. The function was investigated using in vitro assays comprising PAMP/DAMP-stimulation,
downstream signaling and TLR-silencing experiments.
Results: We found that TLR4 was expressed in a biologically active form and responded to both PAMPs and DAMPs
primarily in ER/PR-negative breast cancers. Stimulation of TLR2/4 in vitro induced expression of pro-inflammatory genes
and a gene expression analysis of primary breast cancers showed a strong correlation between TLR4 expression and
expression of pro-inflammatory mediators. In line with this, TLR4 protein expression correlated with a decreased survival.
Conclusions: These findings suggest that TLR4 is expressed in a functional form in ER/PR-negative breast cancers.
Studies regarding TLR4-antagonist therapies should be focusing on ER/PR-negative breast cancer particularly.
Introduction
Breast cancer is the most common form of cancer
among women today [1]. The prognosis of breast cancer
patients varies depending on the breast cancer subtype.
Clinical breast cancer classification is based on expres-
sion of various immunohistochemical markers, with the
hormone receptors being the most important. One of
the worst prognosis subtypes is the triple-negative (TN)
breast cancer subtype, where the malignant cells lack
expression of the hormone receptors, estrogen recep-
tor (ER) and progesterone receptor (PR), and human
epidermal growth factor receptor 2 (Her2) (ER−PR−Her2−).
The treatment options are few for patients with TN breast
cancer [2–4].
Toll-like receptors (TLRs) are a family of receptors
that are expressed on innate immune cells [5]. They are
part of the pattern recognition receptor (PRR) family
and recognize molecular patterns from pathogens
(pathogen-associated molecular patterns; PAMPs) or from
endogenous stress-induced proteins (damage-associated
molecular patterns; DAMPs) [6–9]. Signaling via TLRs
leads to activation of nuclear factor kappa B (NFκB) and a
subsequent expression of pro-inflammatory genes [10].
There are 10 different TLRs (TLR1-10) in humans, and
these are divided into two subgroups depending on cellu-
lar localization; on the surface of the cell (TLR1, TLR2,
TLR4, TLR5 and TLR6), or in vesicles such as endoplas-
mic reticulum, endosomes or lysosomes (TLR3, TLR7,
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TLR8 and TLR9). Lately, expression of different TLRs has
been described in various malignancies, although their
function is as yet unclear [5, 11, 12].
TLR2 and TLR4 respond to the typical PAMP from
Gram-negative bacteria, lipopolysaccharide (LPS). Differ-
ent variants of LPS (from Escherichia coli and Salmon-
ella typhimurium) induce different TLR-intracellular
signals [13]. DAMPs can also bind to and activate TLR2
or TLR4, and two endogenous ligands that are well-
described are HMGB1 and S100A9 [14–19]. To signal
via TLR2 or TLR4, different ligands may also require the
co-receptors CD14 or MD2 [20–23]. All TLR ligands
initiate activation of NFκB, but also mitogen-activated
protein kinase (MAPK) pathways that affect protein
translation and processing rather than transcription can
be activated [24]. TLR4 has previously been shown to be
expressed in breast cancer [25, 26].
The transcriptional factors ERα and NFκB are syner-
gistically interrelated, although their exact interactions
are unknown [10, 27–31]. NFκB is a transcriptional fac-
tor that induces a wide array of pro-inflammatory medi-
ators and is also related to several oncogenic processes
[32]. Both ER and NFκB have previously been shown to
attenuate each other in different ways. In line with this
observation, ER− breast cancers have a stronger pro-
inflammatory phenotype and microenvironment. NFκB
has even been shown to downregulate ERα expression in
breast cancer cells [29], but there is no direct proof that
constitutive NFκB would generate ER− breast cancers in
general. On the other hand, a recent positive synergy be-
tween ER and NFκB was published, where TNFα and es-
trogen were shown to remodulate the ERα-promoter
landscape in an NFκB and FoxA1 dependent manner
resulting in an altered gene expression pattern [33].
In this study we performed an analysis of TLR expres-
sion patterns and function in breast cancer. Using a
carefully validated TLR4-specific antibody for immuno-
histochemistry (IHC), we found that TLR4 protein ex-
pression was primarily present in breast cancers of ER/
PR-negative phenotype. Using three cell lines of ER+
phenotype and four cell lines of the TN phenotype, we
further showed that the expressed TLR4 was biologically
active and hence responding to both PAMPs and DAMPs,
primarily in the TN breast cancer cell lines. Finally, TLR4
protein expression correlated with a decreased survival in
a cohort of 144 primary breast cancer patients. We
propose that novel therapies targeting TLR4 may be of
value, in particular in ER/PR-negative breast cancers.
Methods
Cell culture
The human breast cancer cell lines MCF-7, T47D, MDA-
MB-231 and MDA-MB-468 were purchased from ATCC
and were cultured in RPMI 1640 medium supplemented
with 10 % fetal bovine serum (FBS) (Biosera, Boussens,
France), 1 % sodium pyruvate, 1 % HEPES and penicillin/
streptomycin (100 U/ml and 100 μg/ml respectively);
CAMA-1 (also purchased from ATCC) was cultured in
MEM/EBSS supplemented with 10 % FBS and penicillin/
streptomycin, and SUM-149 and SUM-159 were cultured
in F-12 HAM’S medium supplemented with 5 % FBS,
1 mM L-Glutamine, 1 μg/ml hydrocortisone (BD Bio-
Science, San Diego, CA, USA) and 5 μg/ml insulin (Novo
Nordisk A/S, Måløv, Denmark). The SUM-149 and SUM-
159 cell lines were produced by Professor S Ethier. Media
and supplements were purchased from Thermo Scientific
HyClone (South Logan, UT, USA) unless otherwise stated.
Compounds and cytokine analysis
LPS was purchased from Sigma Aldrich (St Louis, MO,
USA) and originated from S. Typhimurium (LPS1) and
E. Coli (LPS2), respectively. All stimulations were per-
formed for a total of 6 h except for rhS100A9 (20 h). IL-
1β and HMGB1 was from R&D Systems. Recombinant
human S100A9 (rhS100A9) was a gift from Active Bio-
tech AB and a detailed description on endotoxin-free
S100A9 generation and purification has been published
previously [15] and was used in the presence of calcium
and zinc (Ca2+ ≥200 μM; 10 μM ZnCl2 [34, 35]). Super-
natants from stimulated or siRNA transfected cells were
harvested and analyzed using human inflammatory cyto-
kine cytometric bead array (CBA; BD Biosciences, San
Diego, CA, USA) according to the manufacturer’s in-
structions or using IL-6 and IL-8 Quantikine ELISA
(R&D Systems, Minneapolis, MN, USA). Annexin V-
allophycocyanin (APC) and propium iodide (PI) staining
was performed according to the manufacturer’s instruc-
tions (BD Biosciences). The cycloheximide (CHX) exper-
iments (Sigma Aldrich) where performed by adding
10 μg/ml CHX, with or without 100 ng/ml LPS for 6 h.
Preparation of necrotic cell supernatant (NCS)
Confluent monolayers of MDA-MB-231 cells were har-
vested by trypsinization and 3.2 × 106 cells were resus-
pended in 2 ml serum-free RPMI-1640 medium. Necrosis
was induced by performing three freeze-thaw cycles and
NCS was separated from the necrotic cell pellet by
centrifugation.
Tissue microarray (TMA) and immunohistochemistry
The breast cancer cohort analyzed in this study consists
of 144 patients diagnosed with invasive breast cancer at
Skåne University Hospital, Malmö, Sweden, between
2001 and 2002. The cohort and TMA have previously
been described in detail [36–38] and [39]. TMA sections
of 4 μm thickness were mounted onto glass slides and
deparaffinized followed by antigen retrieval using the
PT-link system (DAKO, Glostrup, Denmark) and stained
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in an Autostainer Plus (DAKO) with the EnVisionFlex
High pH-kit (DAKO). Antibody used for TLR4 IHC was
anti-TLR4 NB100-56566 at 1:250 (Novus Biologicals,
Littleton, CO, USA). TLR4 expression in TMA tumor
samples was estimated as cytoplasmic staining intensity
(0 = negative, 1 = weak, 2 =moderate, 3 = strong intensity
and 4 = very strong intensity).
Ethical considerations
Ethical permit was obtained from the regional ethical
committee at Lund University (Dnr 447/07), waiving the
requirement for signed informed consent. Patients were
offered to opt out of research. Ethical permission for
using blood from healthy blood donors was obtained
from the regional ethical committee at Lund University
(Dnr 2012/689).
Gene expression profile array
The publicly available database R2: microarray analysis
and visualization platform [40]; Tumor breast EXPO-
351 was used for gene expression profile analysis.
Quantitative real-time PCR (RT-qPCR)
RNeasy Plus kit was used to extract total RNA according
to the manufacturer’s instructions (Qiagen, Hilden, MD,
USA). Random hexamers and the M-MuLV reverse tran-
scriptase enzyme (Thermo Scientific) was used and
quantitative real-time PCR (RT-qPCR) were performed
in triplicates for the genes analyzed using Maxima SYBR
Green/Rox (Thermo Scientific) according to the manu-
facturer’s instructions. RT-qPCR analysis was performed
on the Mx3005P QPCR system (Agilent Technologies,
Santa Clara, CA, USA) and the relative mRNA expres-
sion was normalized to YWHAZ, UBC and SDHA and
calculated using the comparative cycle threshold (Ct)
method [41]. For primers see Additional file 1: Table S1.
Transient transfections
siRNA transfections were performed using Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA, USA): 2 μM of the
following silencer select siRNA oligonucleotides from
Ambion (Carlsbad, CA, USA) were used; Silencer Select
Negative Control #2: 4390846, siTLR2 #1: s168, siTLR2
#2: s170, siTLR4 #1: s14194, siTLR4 #2: s14195. Analyses
were performed 48 h and 72 h post transfection. For lucif-
erase assays, breast cancer cells were co-transfected
using Lipofectamine 2000 with a total of 0.6 μg pNFκB-
luciferase (BD Biosciences) and 0.06 μg TK-renilla-
luciferase (Promega, Madison, WI, USA) plasmids and
was subsequently analyzed using Dual-Luciferase Reporter
System (Promega). For TLR4 transfections breast cancer
cells were transfected using Lipofectamine 2000 with a
total of 1.0 μg pDUO-MD2/hTLR4 or pUNOI-hTLR4-
GFP (Invivogen, San Diego, CA, USA) per 24 wells for
72 h or 48 h, respectively, and was subsequently analyzed
using immunofluorescence (×40 magnification) or ELISA
as described in the figure legends.
Statistical analyses
Graph Pad Prism software was used to perform analysis
of variance (ANOVA) or Students t test for the in vitro
experiments as indicated. Spearman's Rho and the chi-
square (χ2) test was used for correlation analysis and
Kaplan-Meier analysis with the log-rank test was used to
illustrate differences in survival. All statistical tests were
two sided and P ≤0.05 was considered significant. Calcu-
lations were performed with IBM SPSS Statistics version
19.0 (SPSS Inc).
Results
TLR and co-receptor mRNA expression pattern in breast
cancer cell lines
Most studies of TLRs in breast cancer have been per-
formed using the ER+ cell line MCF-7 and the TN cell
line MDA-MB-231 [5]. To our knowledge, a detailed
comparison between ER+ and TN cell lines or cancers
has not been published. We initially performed a broad
analysis on TLR and TLR2/4 co-receptor (CD14 and
MD2) mRNA expression patterns in various breast can-
cer cell lines. We used three cell lines with an ER+PR+
phenotype (MCF-7, T47D and CAMA-1) and four with
an ER−PR−Her2− (TN) phenotype (MDA-MB-231; MDA-
MB-468, SUM-149 and SUM-159). As shown in Fig. 1a-c,
TLR2,TLR3 and TLR4 were preferentially expressed in the
TN cell lines while TLR9 was more generally expressed
(Fig. 1d). Only MDA-MB-468 had low/absent mRNA ex-
pression levels of TLR2 and TLR4 of the TN cell lines.
Similarly, the TLR4 co-receptors CD14 and MD2 were
expressed primarily in the TN cells lines (Fig. 1e, f ). Again,
the TN cell line MDA-MB-468 stood out with high CD14
mRNA expression levels, but low MD2 levels (Fig. 1e, f ).
This means that three out of the four TN breast cancer
cell lines had the necessary proteins for a functional TLR4
signal to occur.
The TLRs are functional and activation promotes
expression of pro-inflammatory genes
To investigate whether the expressed TLRs were
functional in the breast cancer cells following LPS
stimulation, we analyzed the expression levels of some
pro-inflammatory genes that are known targets for NFκB.
The pro-inflammatory cytokines IL-6 and IL-8 were
expressed at both protein (Fig. 2a and b) and mRNA
(Fig. 2c and d) levels and only in the TN breast cancer
cells but not the ER+ breast cancer cells. The TLR2/
4-ligand LPS induces different TLR downstream signaling
pathways when originating from different bacterial strains
[13]. When the breast cancer cells were stimulated with
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LPS for 6 h (LPS1 from S. Typhimurium and LPS2 from
E. Coli), we could see that IL-6, IL-8 and TNFα were in-
duced by both LPS1 and LPS2 in the MDA-MB-231,
SUM-149 and SUM-159 cell lines, but not the MDA-MB-
468 cells with inherent low expression of TLR4 (Fig. 2b).
A slight effect of LPS2 was seen in the TLR2/4-negative
cell line, CAMA-1, which might represent unspecific
binding to other receptors. This was supported by the
finding that the mRNA levels of IL-6 and IL-8 increased in
a similar manner in all TN cell lines except MDA-MB-
468, and not in the CAMA cell line (Fig. 3a and data not
shown). Interestingly, TLR signaling affected not only the
transcription of IL-6 and IL-8, but also the protein transla-
tion as judged by cycloheximide (CHX) experiments
showing a decreased release of both IL-6 and IL-8 after
LPS1 stimulation upon simultaneous treatment with LPS
and CHX (Fig. 3b).
A TLR4-specific DAMP induces pro-inflammatory
cytokines in breast cancer cells
We further investigated whether DAMPs could induce
TLR2/4-signaling in TN cell lines (MDA-MB-231, SUM-
149 and SUM-159) and found that LPS (LPS1 and
LPS2), but not the endogenous DAMP HMGB1, signifi-
cantly induced IL-6 and IL-8 release in MDA-MB-231
cells and SUM-159 cells (Fig. 3c and e), whereas in
SUM-149 cells LPS2 induced IL-6 and IL-8 release
primarily (Fig. 3d). This finding might reflect that TLR2/
4-induced transcription v/s translation might be differ-














































































































































































































































































Fig. 1 Breast cancer cell line mRNA expression levels of Toll-like receptor 2 (TLR2), TLR3, TLR4, TLR9 and co-receptors CD14 and MD2. a-f The relative
expression of indicated mRNA using quantitative real-time PCR (QPCR) on mRNA from the cell lines indicated. Error bars standard error of the mean:
n = 6 − 9; ***P <0.001 (analysis of variance)
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Fig. 2 (See legend on next page.)
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as a positive control. Using dual luciferase assays and an
NFκB reporter, we confirmed that LPS stimulation of
MDA-MB-231 cells induced activation of NFκB but
HMGB1 did not (Fig. 3f ). We continued with another
cancer-related DAMP reported to be a TLR4 ligand, the
S100A9 protein [35]. Indeed, stimulating MDA-MB-231,
SUM-149 and SUM-159 cells with rS100A9 for 20 h
induced a significant increase in both IL-6 and IL-8
release (Fig. 3g). We also tested whether stimulating
with HMGB1 for 20 h would induce cytokine release
but with negative results (data not shown). Finally, by
introducing the MD2/TLR4 complex (pDUO-MD2/
TLR4) in otherwise negative MCF-7 cells, we could see a
significant expression of both IL-6 and IL-8 as compared
to control MCF-7 cells (Fig. 3h). pDUO-MD2/TLR4 is an
expression vector that is designed to co-express the MD2
and TLR4 genes needed to interact with each other for
functional signaling to occur upon ligand binding [42].
Constitutive expression of IL-6 and IL-8 is inhibited by
silencing of TLR4
The impact of TLR4 signaling (possibly by endogenous
DAMPs) on the constitutive expression of IL-6 and IL-8
seen in the MDA-MB-231 cells was analyzed. To this end
we used negative control (nc) siRNA or siRNA specific for
TLR2 (siTLR2#1 and #2) and TLR4 (siTLR4#1 and #2)
(Fig. 4a), and analyzed the IL-6 and IL-8 levels 72 h post
transfection. Both siTLR2 and siTLR4 slightly decreased
the endogenous levels of IL-6 and IL-8 (Fig. 4b).
TLR2/4 expression affects migration and invasion
The TLR2/4-induced pro-inflammatory cytokines can be
chemoattractants for myeloid cells. We therefore next
investigated whether primary human CD11b+ myeloid
cells would migrate toward supernatants collected from
breast cancer cells with a TN phenotype as compared to
ER+ breast cancer cells. Indeed, primary human myeloid
cells migrated significantly more to supernatants collected
from MDA-MB-231 cells as compared to from ER+ MCF-
7 or T47D cells, but as expected also to the TLR4-negative,
but pro-inflammatory cytokine-secreting, MDA-MB-468
cells (Fig. 4c).
Other parameters that might be affected by TLR4 ex-
pression in breast cancer cells were also investigated; inva-
sion, apoptosis and proliferation (Fig. 4d and Additional
file 2: Figure S1A-B). In summary, invasion into matrigel
invasion chambers by MDA-MB-231 breast cancer cells
was increased when the TLR2/4 ligand LPS was added to
the invading cells (Fig. 4d). Apoptosis in MDA-MB-231
breast cancer cells where TLR2 or TLR4 was silenced gave
either conflicting results (TLR2) or was not affected
(TLR4) (Additional file 2: Figure S1A), and finally
proliferation using 3H-incorporation assays of MDA-
MB-231 breast cancer cells where TLR4 was silenced
was not affected as compared to control (Additional
file 2: Figure S1B).
To finally evaluate if other relevant TLRs were func-
tional in the TN breast cancer cells we also performed
stimulations of MDA-MB-231 cells with necrotic cell
supernatant (NCS; TLR3 ligands [43]). Release of IL-8
but not IL-6 was affected by addition of NCS in a
concentration-dependent manner (see Additional file 2:
Figure S1C).
TLR4 is expressed in ER/PR-negative breast cancers and
correlates with poor survival
TLR proteins are difficult to analyze because the anti-
body specificity is generally poor. We carefully evaluated
several antibodies and found one to be highly specific.
This antibody was confirmed first by using human tonsil
tissue as positive control, showing the typical pattern of
TLR4-expressing cells surrounding the follicles (Fig. 5a).
Having optimized IHC, we subsequently stained formalin-
fixed and paraffin-embedded cell pellets of the cell lines
used in this study. All ER+ cell lines were negative for
TLR4, whereas three out of four TN cell lines displayed
marked cytoplasmic positivity, corroborating our mRNA
results (Fig. 5b). The cytoplasmic localization of TLR4 in
breast cancer cells was supported by transfection of breast
cancer cells using a green fluorescent protein (GFP)-
tagged TLR4 plasmid (pUNOI-hTLR4-GFP) (Fig. 5c). We
found that in cells expressing both the TLR4 co-receptors
MD2 and CD14 (MDA-MB-231 cells; Fig. 5c left) TLR4-
GFP was expressed in a vesicular pattern in the cytosol,
whereas in breast cancer cells lacking both MD2 and
CD14 (MCF-7 cells; Fig. 5c right), TLR4-GFP was ex-
pressed evenly in the cytoplasm.
A TMA of 144 breast cancer patients was subse-
quently stained and analyzed for correlation with other
histological and clinical parameters. The staining was
judged as cytoplasmic staining of intensities 0, 1, 2, 3
and 4 (see “Methods”) (Fig. 6a). When the analysis was
(See figure on previous page.)
Fig. 2 Lipolysaccharide (LPS) induced cytokine release in human breast cancer cells in vitro. Release of cytokines by breast cancer cells of
estrogen receptor-positive (ER+) origin (a) and triple-negative (TN) origin (b) was analyzed using cytokine bead array (CBA). Unstimulated breast
cancer cells of TN origin (b) produce IL-6 and IL-8 at high levels. LPS1 (from S. Typhimurium) and LPS2 (from E. Coli) stimulation for 6 h induced
release of IL-8, IL-6 and TNFα from indicated breast cancer cell lines. At least three experiments were performed for each cell line. The relative
mRNA expression of IL-6 (c) and IL-8 (d) in unstimulated cells was measured using quantitative real-time PCR (QPCR). At least five experiments
were performed for each cell line. Error bars standard error of the mean; ***P <0.001 (analysis of variance)
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performed these cytosolic scoring parameters were
grouped into 0–2 (0) and 3–4 (1) critical cutoffs. Table 1
shows the clinical parameters and correlations found
with the TLR4-specific antibody. The intensity groups
3–4 (1) correlated significantly with the ER/PR-negative
patient group and the basal-like status marker CK5. It
did not correlate to Her2 expression (or lack of expres-
sion), however (Tables 1, 2 and 3). Tables 2 and 3 specif-
ically show the correlation between Her2 and TLR4.
Survival curves using the two cutoff groups indicate that
as expected, the group with high TLR4 expression had

























































































































































































































































































































































































































































































































































































Fig. 3 Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular pattern (DAMPs) induce cytokine expression in human
breast cancer cells in vitro. a Relative expression of IL-6 and IL-8 mRNAs after 6 h stimulation with lipopolysaccharide 1 (LPS1) and LPS2, using
quantitative real-time PCR (QPCR) on mRNA from the cell lines indicated; n = 6. Error bars standard error of the mean (SEM); ***P <0.001 (analysis
of variance (ANOVA)). b Release of IL-6 and IL-8 after stimulation with LPS1 and cycloheximide for 6 h, using ELISA on supernatants from
stimulated MDA-MB-231 cells; n = 3. c-e Relative release of IL-6 and IL-8 after stimulation with LPS1, LPS2, the DAMP HMGB1 or IL-1β for 6 h, using
ELISA on supernatants from stimulated MDA-MB-231 cells (c), SUM-149 cells (d) and SUM-159 cells (e); n = 10. Error bars SEM; *P <0.05,
***P <0.001 (ANOVA). f Dual luciferase reporter assays of MDA-MB-231 cells transfected with an NFκB reporter. TK-Renilla was co-transfected as
control (Ctrl). LPS1, LPS2, HMGB1 or IL-1β was added to stimulate NFκB activity as described in “Methods”; n = 14. Error bars SEM; ***P <0.001
(ANOVA). g The relative release of IL-6 and IL-8 after stimulation with the DAMP S100A9 for 20 h, using ELISA on supernatants from stimulated
MDA-MB-231, SUM-149 and SUM-159 cells; n = 6. Error bars SEM. *P <0.05, ***P <0.001 (ANOVA). h Transient transfection of pDUO-MD2/hTLR4 for
72 h in MCF-7 cells induces release of both IL-6 and IL-8 measured by ELISA; n = 6. Error bars SEM; *P <0.05, ***P <0.001 (Students t test)
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(Fig. 6b). Membranous staining was also scored (0, 1)
but there was no strong correlation (data not shown).
Finally, using a publicly available data site (R2: micro-
array analysis and visualization platform [40]; Tumor
breast EXPO-351) with gene expression profiles of 351
primary breast cancers, we found positive correlation be-
tween expression of TLR4 mRNA and IL-6 (r value
0.231, P = 1.3e-05) (Fig. 6c).
Discussion
Breast cancers with an ER-negative phenotype have
previously been shown to promote a strong pro-
inflammatory microenvironment [44]. Furthermore, his-
torically there is a negative relationship between ERα and
NFκB that has previously been described in depth
[10, 27–30]. Despite the fact that ER signaling can in-
hibit NFκB activity and vice versa, there is no evidence
that the development of ER-negative breast tumors are
caused by constitutive NFκB activity. Rather, it may be a
result of the typical molecular gene landscapes found in
luminal A compared to basal breast cancers, respectively.
A link between PRR, e.g., TLR-induced activation of NFκB
in breast cancer and its relation to expression of ER, has
not been described. Both IL-6 and IL-8 can be highly
expressed in TN breast cancers and this has partly been
attributed to constitutively active NFκB [44]. In order to
investigate whether TLRs, which are known to induce
strong activation of NFκB, are expressed primarily in

















































































































































































































Fig. 4 Toll-like receptor 4 (TLR4) silencing decreases endogenous
levels of pro-inflammatory cytokines. a Effect of TLR2/4 silencing in
breast cancer cells transfected with negative control (nc) siRNA, or
siRNA directed against TLR2 mRNA (si#1 and si#2) or TLR4 mRNA
(si#1 and si#2) was analyzed using quantitative real-time PCR;
***P <0.001 (analysis of variance (ANOVA)). b IL-6 (left) and IL-8 (right)
ELISA on supernatants from MDA-MB-231 breast cancer cells
transfected with nc siRNA, or siRNA directed against TLR2 mRNA
(si#1 and si#2) or TLR4 mRNA (si#1 and si#2); n = 4. Error bars standard
error of the mean (SEM); *P <0.05, **P <0.01, ***P <0.001 (ANOVA).
c Boyden chamber migration assays. Migration of primary human
myeloid cells towards supernatants from different cell lines indicated.
Human primary peripheral blood mononuclear cells were isolated as
previously described [48] and allowed to migrate through a Costar
Transwell® Permeable Support 8.0-μm 24-well plate (Corning) to the
supernatants of breast cancer supernatants cultured under serum-free
conditions. Percentage of migrated CD11b+ cells was analyzed using a
flow cytometer and CD11b-APC antibodies (BD Sciences); n = 4. Error
bars SEM; *P <0.05, **P <0.01, ***P <0.001 (ANOVA). d Matrigel invasion
assays. Invasion of lipopolysaccharide (LPS)-stimulated/un-stimulated
MDA-MB-231 cells into matrigel invasion chambers (BD Sciences) as
indicated: 25 × 103 MDA-MB-231 cells were stimulated or not with
LPS and allowed to invade from 72 h. Amount of invaded cells was
analyzed using crystal violet staining and manual counting in four
separate experiments; n = 4. Error bars SEM; *P <0.05, **P <0.01,
***P <0.001 (Student’s t test)
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of pro-inflammatory genes in the same, we investigated
the functional role of TLRs and co-receptors in breast
cancer.
In immune cells, TLR expression is generally inhibited
by prolonged activation of NFκB [45]. In contrast, our
findings show that TLRs (TLR2, TLR 3, TLR 4) are
preferentially expressed in TN breast cancer cell lines
with constitutive NFκB activity, suggesting that the TLRs
may be responsible for the NFκB activation pathway ra-
ther than induced by the same. Although introduction of
a functional MD2/TLR4 complex in an ER+ cell line has













Fig. 5 Analysis of Toll-like receptor 4 (TLR4) protein expression in tonsil and breast cancer cells lines. Immunohistochemical analysis using an
anti-human TLR4-specific antibody on paraffin-embedded tonsil (a) or cell pellets from the cell lines indicated (b). Arrow indicates the membranous
staining. c MDA-MB-231 cells expressing the TLR co-receptors MD2 and CD14 but not ERα left), and MCF-7 cells expressing ERα but not MD2 or CD14
(right) were transfected with GFP-tagged hTLR4 (pUNOI-hTLR4-GFP; Invivogen) for 48 h. Localization was investigated using immunofluorescence micros-
copy. The green fluorescent protein (GFP)-tagged hTLR4 was expressed in a vesicular pattern in the cytoplasm of MDA-MB-231 cells and evenly in the
cytoplasm of MCF-7 cells. Arrow indicates the vesicular pattern. ER+ estrogen receptor-positive, TN triple-negative
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cytokines, silencing of TLR4 in TN cells only caused a
slight decrease in pro-inflammatory mediator release, in-
dicating that the constitutive NFκB activation seen in
TN cells in general is caused by another mechanism
[44]. Apart from MDA-MB-468, the TN breast cancer
cells were also demonstrated to express the co-receptors
CD14 and MD2 meaning that they harbor the necessary
proteins for a functional TLR4 signal to occur [20–22].
The exception, MDA-MB-468, only expressed CD14 and
in line with this showed no biological TLR function. In
the patient cohort we found correlation between TLR4
expression and ER/PR-negative tumors, but not TN tu-
mors. This strengthens the interrelationship between
TLR4, ER and NFκB activity, as expression of HER2 was
not correlated in the TLR4-expressing primary tumors.
We did not perform our in vitro analyses on any Her2+
breast cancer cell line. Interestingly, the typical mem-
brane staining seen in immune cells was not as obvious
in the malignant cells, indicating that different regulation
of TLR expression and signaling could be possible in can-
cers. This was previously described in neuroblastoma cells
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Fig. 6 Toll-like receptor 4 (TLR4) expression in breast tumors and survival curves. a Immunohistochemical TLR4 expression sample images from
breast cancer tissue microarray cores, from left to right: negative (0), weak (1), moderate (2), strong (3) and very strong (4). Boxes with magnification
and arrows to indicate localization (black arrow membranous, green arrow leukocyte, red arrow cytoplasmic staining. b Kaplan-Meier curves illustrating
differences in recurrence-free survival according to TLR4 cytoplasmic expression in breast tumors. Cytosolic scoring parameters were grouped into 0–2
(0) and 3–4 (1) critical cutoffs. c Gene expression profile analysis of TLR4 mRNA in relation to IL-6 in (R2: microarray analysis and visualization platform
[40]; Tumor breast EXPO-351)
Table 1 Correlation between TLR4 expression and clinicopathologic







Age −0,042 0,629 135
Nodal stage 0,042 0,646 122
Tumor size −0,006 0,944 135
Ki67 0,003 0,971 117
nhg 0,094 0,276 135
Her2 subtype 0,158 0,072 131
ER status −0,170 0,049* 135
PR status −0,206 0,016* 135
CK5 0,184 0,037* 129
*P <0.05 using SPSS and Spearman’s Rho test. Her2 human epidermal growth
factor receptor 2, ER estrogen receptor, PR progesterone receptor, nhg
Nottingham histological grade
Table 2 Crosstab over Toll-like receptor 4 (TLR4) (0, 1) and
Her2 (0, 1)
TLR4 (0) TLR4 (1) Total
Her2 (0) 83 33 116
(1) 6 6 12
Chi square test value 2.366, P = 0.124. Her2 human epidermal growth factor
receptor 2
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[46] and is also supported by our finding that a GFP-
tagged hTLR4 primarily showed a vesicular cytoplasmic
localization in breast cancer cells. Furthermore and sup-
porting this observation, it was recently reported that the
TLR4-specific DAMP, S100A9, needs to be internalized to
be able to signal via TLR4 [15]. Indeed, scoring of mem-
brane TLR4 expression in breast cancer lesions did not re-
veal as much as that of cytoplasmic staining, and both
TLR2 and TLR4 have been reported to be expressed intra-
cellularly as well [47].
The DAMP, HMGB1, has previously been shown to sig-
nal via TLR4 in myeloid cells [6, 19]. Although we have
also previously shown this in primary myeloid cells [48],
we did not see an effect of HMGB1 on breast cancer cells
in vitro. This could be due to different culture conditions,
or to receptor expression patterns in myeloid as compared
to cancer cells which might also reflect the fact that differ-
ent sources of LPS generate different signals in the differ-
ent cell lines in this study. Instead, we could show that the
DAMP, S100A9, also induced pro-inflammatory proteins
in breast cancer cells expressing TLR4.
It has previously been shown that NFκB [29] and tar-
gets (IL-6) [49] can downregulate ERα. We also investi-
gated whether overexpression of TLR4 would affect ERα
expression per se in ER+ MCF-7 cells. We did see a
slight although non-significant decrease of ERα after
72 h (data not shown), a finding that is probably ex-
plained by the significantly increased levels of IL-6 we
observed in these experiments (Fig. 3h). In spite of this,
we suggest that the ER/PR-negative breast cancer sub-
type probably is not caused by expression of TLRs and
their downstream mediators, but rather further affected
by them. Perhaps the expression of TLRs is even af-
fected by the ERα/FoxA1/GATA3 network [50]. We
show that both PAMPs and DAMPs induced release
of pro-inflammatory mediators in ER/PR-negative breast
cancer cells in vitro, a process that was regulated both at
the transcriptional and post-transcriptional level. This
means that although ER-negative breast cancer cells ex-
press high endogenous levels of pro-inflammatory media-
tors, a functional TLR4 is still likely to enhance their
phenotype and surrounding inflammatory microenviron-
ment, and this is also reflected by the decreased
recurrence-free survival seen in the patients with tumors
expressing TLR4 at high levels. In support of this, previ-
ous studies have shown that TLR4 expression promotes
metastasis in a breast cancer model, an effect that was
even enhanced by Paclitaxel [25, 26].
Conclusion
The findings presented in this study suggest that TLR4 is
expressed in a functional form in ER/PR-negative breast
cancers primarily. We suggest that TLR4 should be
viewed as a possible therapeutic target in ER/PR-negative
breast cancers to decrease the pro-inflammatory environ-
ment and hence the metastatic spread.
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TLR2 mRNA (si#1 and si#2) or TLR4 mRNA (si#1 and si#2). TLR2 (si#1 and
#2) gave contradicting results while TLR4 si#1 and #2 gave no effect
(n = 3). Error bars indicate standard error of the mean (SEM); *P <0.05,
**P <0.01, ***P <0.001 (analysis of variance (ANOVA)). B 3H-incorporation
assay using previously published methods [48] to investigate proliferation
of MDA-MB-231 cells transfected with negative control (nc) siRNA, or
siRNA directed against TLR2 mRNA (si#1 and si#2) or TLR4 mRNA (si#1 and
si#2) (n = 6). Error bars indicate SEM; *P <0.05 ** P < 0.01, ***P <0.001
(ANOVA). C IL-6 (left) and IL-8 (right) ELISA performed on supernatants
from MDA-MB-231 breast cancer cells stimulated with increasing
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25 μl = 1:8 (n = 4). Error bars indicate SEM; *P <0.05, **P <0.01, ***P <0.001
(ANOVA). (PDF 176 kb)
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